Antag Therapeutics
PrivateLast Round
Series A
Dec 4, 2024
Total Funding Raised
$90M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antag Therapeutics is a biopharmaceutical company that develops peptide-based GIP receptor antagonist therapies for obesity and cardiometabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antag Therapeutics Comparables
Compare Antag Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ousia Pharma | 82% | |
| Alveus Therapeutics | 80% | |
| Pep2Tango Therapeutics Inc. | 74% | |
Antag Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 4, 2024 | ||||
| Seed | Jun 26, 2017 | ||||
| Seed | Apr 1, 2017 |
Key People
Founding team and executive leadership
Antag Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pictet Group | Series A |
| Viva Biotech | Series A |
| Versant Ventures | Series A |
| Novo Holdings | Series A, Seed |
| The Export and Investment Fund of Denmark | Series A |
| SR One | Series A |
| Longview Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Presenting at the American Diabetes Association Scientific Sessions in June 2026.
- Jan 8, 2025
Dr. Joerg Moeller appointed as the new Chief Executive Officer.
Antag Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Antag Therapeutics's valuation, stock price, and market status.